- Q3 non-GAAP EPS of $0.73 beat by $0.01, and revenue of $5.14B rose 1.4% Y/Y, beating by $90M.
- FY26 adjusted EPS guidance fell to $3.16–$3.18 versus $3.23 consensus.
- The company cited impact from a recent cybersecurity incident for the outlook cut.
- Boston Scientific expects to end FY26 with a Q4 sales decline.
- Shares fell sharply in premarket trading on Wednesday after the guidance cut.
Quotes
“citing impact from a recent cybersecurity incident”
“Boston Scientific lowered its outlook, as it expects to end a difficult year with a fourth-quarter sales decline.”